|
| |
CellAura, the leading producer of
fluorescence reagents for drug discovery and life sciences research, today
announced a development partnership with Cisbio Bioassays
Latest success for Nottingham biopharma cluster
Nottingham, UK October 22, 2009 –CellAura, the leading producer of
fluorescence reagents for drug discovery and life sciences research, today
announced a development partnership with Cisbio Bioassays. Under the terms of
the agreement, CellAura will provide pharmacologically validated reagents to
Cisbio Bioassays that will be applied to Cisbio Bioassays’ Tag-lite™ range of
non-radioactive assays for cellular studies.
Commenting on the collaboration, CellAura CEO Dai Hayward said: "Maximising
cellular information is increasingly seen as the key to successful drug
discovery. CellAura combines world-renowned expertise from the University of
Nottingham in the fields of synthetic chemistry and molecular pharmacology to
produce high quality fluorescent receptor ligands as key components in drug
candidate screening assays and imaging techniques. This new partnership with
Cisbio Bioassays, which is one of the leaders in bioassays for cell surface
receptor and functional studies, recognizes our rapid progress and is a major
milestone."
CellAura will develop a number of reagents for Cisbio Bioassays’ Tag-lite™
range. Tag-lite, part of Cisbio Bioassays’ comprehensive HTRF cellular platform,
provides a homogeneous, non-radioactive and cost-effective alternative for the
study of cell surface receptor dimerization and ligand binding.
François Degorce, head of marketing for Cisbio Bioassays added: "GPCR and more
generally cell surface receptor investigation are currently among the hottest
topics in drug discovery. To enhance our Tag-lite platform addressing this area,
we seek out partnerships with the best experts in their respective fields, and
are pleased to collaborate with CellAura for the development of non-radioactive
fluorescent ligands."
CellAura will also retain rights for the reagents developed for use in their own
range of assays for certain markets. Financial details were not disclosed.
-ends-
Editors notes:
CellAura is a spin out company from the University of Nottingham: combining
world-renowned expertise in the fields of synthetic chemistry and molecular
pharmacology we produce high quality fluorescent G-protein coupled receptor
ligands for use in molecular pharmacology and imaging at the single cell level.
Applications include:
High Content Screening - Live cell imaging of receptor-ligand binding,
displacement, and receptor internalisation.
Ligand Binding Kinetics - Real-time analysis of ligand association and
dissociation rates to determine receptor affinity.
Dual Readout Binding and Function (eg Ca++ signalling) - Distinguishes agonists,
antagonists/inverse agonists, off-target effects and non-binders in one assay,
to eliminate false hits and reduce follow-on screening.
High Throughput Screening - Dynamic or endpoint binding and displacement
Fluorescence Intensity assays.
Confocal Microscopy - Localise receptor distribution in tissue sections, cell
cultures and single cells
Fluorescence Correlation Spectroscopy (FCS) - Real-time analysis of single
molecule ligand-receptor interactions.
Fluorescent Ligand Binding - Increased safety, reduced disposal cost and
environmental impact vs radioligand binding.
Fluorescence Activated Cell Sorting (FACS) - No need to generate
fluorescence-tagged receptor antibodies, select receptor expressing cells using
a direct receptor-binding ligand.
For more information visit www.cellaura.com
Corporate Inquiries
Dai Hayward, CEO
CellAura, BioCity Nottingham NG1 1GF UK
Tel +44 (0)7888 833859 Email:
dai.hayward@cellaura.com
Media Inquiries
Richard Hayhurst, Schwartz Communications
Tel +44 (0) 7711821527 Email:
rhayhurst@schwartz-pr.com
CellAura signs major supply deal with leading international drug discovery group
| |
|
